Pangea Bio (a trading name of Pangea Botanica Ltd), develops transformative medicines to treat neurological and neuropsychiatric conditions. Their proprietary discovery platform combines technology across computational metabolomics and generative AI to uncover promising neuroactive molecules from medicinal plants. Pangea Bio’s lead program, a proprietary small molecule targeting the TrkB receptor — a pivotal neuroplasticity regulator— shows compelling data across schizophrenia, Parkinson’s and Alzheimer’s disease. Pangea’s spin off Kanna Health Ltd is a clinical stage biotech company developing novel therapeutics to address areas of significant unmet need in sexual and mental health and got certified together with Pangea Bio.
Keywords: biotech, drug discovery, drug development, pharma, ai
Sector: Service with Minor Environmental Footprint
Size: 10-49 employees
B Corp Certified – Impact Score: 85.5
